Hubert Chen has been appointed chief medical officer of San Diego biotech Metacrine. Chen most recently worked as chief medical officer of Pfenex (NYSE American: [[ticker:PFNX]]). Metacrine develops drugs for liver and gastrointestinal diseases. Last year, Metacrine raised $22 million in Series B financing. The company plans to test its lead drug, MET409, as a treatment for the fatty liver disease nonalcoholic steatohepatitis.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
